{
  "question": "Was today a new drug approved?",
  "url": "https://was.today/a-new-drug-approved",
  "verdict": "no",
  "headline": "NO",
  "answer": "No — the latest FDA action was Oct. 26, when talazoparib plus enzalutamide got an expanded indication, not a new drug.",
  "details": [
    "Oct. 26: Talzenna plus Xtandi expanded to HRR-mutated mCSPC",
    "Oct. 23: Awiqli (insulin icodec) approved for kids 10+",
    "Oct. 20: Hibsago (bepirovirsen) approved for chronic hepatitis B"
  ],
  "sources": [
    {
      "title": "U.S. Food and Drug Administration (.gov)",
      "url": "https://www.accessdata.fda.gov/scripts/CDER/daf/index.cfm?event=report.page"
    },
    {
      "title": "Optum Business",
      "url": "https://business.optum.com/en/support/professionalrx-resources/rx-news-102326.html"
    },
    {
      "title": "American Pharmaceutical Review",
      "url": "https://www.americanpharmaceuticalreview.com/1448-News/?alpi_4606=3&catid=25811#1"
    },
    {
      "title": "Biopharma Asia",
      "url": "https://biopharma-asia.com/sections/fda-expands-talzenna-plus-xtandi-approval-to-earlier-metastatic-prostate-cancer-setting/"
    },
    {
      "title": "The Script Pad",
      "url": "https://thescriptpad.com/articles/fda-approves-talazoparib-enzalutamide-hrr-metastatic-castration-sensitive-prostate-cancer"
    },
    {
      "title": "The Script Pad",
      "url": "https://thescriptpad.com/articles/fda-approves-awiqli-insulin-icodec-pediatric-type-2-diabetes"
    }
  ],
  "date": "2026-10-27",
  "place": null,
  "permalink": "https://was.today/a-new-drug-approved/2026-10-27",
  "scope": "global",
  "volatile": true,
  "generatedAt": "2026-10-27T08:55:18.170Z"
}